全文获取类型
收费全文 | 481篇 |
免费 | 43篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 13篇 |
妇产科学 | 15篇 |
基础医学 | 57篇 |
口腔科学 | 10篇 |
临床医学 | 43篇 |
内科学 | 170篇 |
皮肤病学 | 7篇 |
神经病学 | 26篇 |
特种医学 | 25篇 |
外科学 | 53篇 |
综合类 | 18篇 |
预防医学 | 23篇 |
眼科学 | 2篇 |
药学 | 33篇 |
中国医学 | 2篇 |
肿瘤学 | 28篇 |
出版年
2024年 | 1篇 |
2023年 | 6篇 |
2022年 | 12篇 |
2021年 | 19篇 |
2020年 | 7篇 |
2019年 | 17篇 |
2018年 | 17篇 |
2017年 | 10篇 |
2016年 | 16篇 |
2015年 | 15篇 |
2014年 | 18篇 |
2013年 | 20篇 |
2012年 | 26篇 |
2011年 | 37篇 |
2010年 | 18篇 |
2009年 | 22篇 |
2008年 | 17篇 |
2007年 | 27篇 |
2006年 | 19篇 |
2005年 | 25篇 |
2004年 | 14篇 |
2003年 | 20篇 |
2002年 | 28篇 |
2001年 | 10篇 |
2000年 | 12篇 |
1999年 | 14篇 |
1998年 | 5篇 |
1997年 | 13篇 |
1996年 | 4篇 |
1995年 | 4篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有526条查询结果,搜索用时 15 毫秒
521.
Heterozygous mutations of the KCNJ11 gene encoding the Kir6.2 subunit of the ATP-sensitive potassium channel (K(ATP) channel) of the pancreatic β-cell cause diabetes in about 30-60% of all permanent neonatal diabetes mellitus cases diagnosed before 6 months of age. The K(ATP) channel plays an essential role in the regulation of the electrical status of the membrane through which the secretion of insulin is activated. Transient neonatal diabetes mellitus due to KCNJ11 mutations is less frequent than abnormalities affecting the imprinted region of chromosome 6q24. We studied the genetic basis of two Cypriot patients who developed diabetes before 6 months of age. They both carried mutations of the KCNJ11 gene. The R201H mutation was identified in a patient who developed hyperglycemia and ketoacidosis at the age of 40 d and was successfully transferred to sulphonylureas which activate the channel through an ATP independent route. The R50Q mutation was identified in a child diagnosed at day 45 after birth with remission of his diabetes at 9 months of age. The same defect was identified both in his asymptomatic mother and the recently diagnosed 'type 2' diabetic maternal grandmother. The remission-relapse mechanism in cases of transient neonatal diabetes is not known. Nevertheless, it is possible that the residue of the mutation within the Kir6.2 molecule is associated with the sensitivity to ATP reflecting to the severity of the diabetic phenotype. 相似文献
522.
523.
Most genotyping methods for known single-nucleotide polymorphisms (SNPs) are based on hybridization with allele-specific probes, oligonucleotide ligation reaction (OLR), primer extension or invasive cleavage. OLR offers superior specificity because it involves two recognition events; namely, the hybridization of an allele-specific probe and a common probe to adjacent positions on target DNA. OLR products can be detected by microtiter well-based colorimetric, time-resolved fluorimetric or chemiluminometric assays, electrophoresis, microarrays, microspheres, and homogeneous fluorimetric or colorimetric assays. We have developed a simple, robust, and low-cost disposable biosensor in dry-reagent format, which allows visual genotyping with no need for instrumentation. The OLR mixture contains a biotinylated common probe and an allele-specific probe with a (dA)(20) segment at the 3'-end. OLR products are denatured and applied to the biosensor next to gold nanoparticles that are decorated with oligo(dT) strands. The sensor is immersed in the appropriate buffer and all components migrate by capillary action. The OLR product is captured by immobilized streptavidin at the test zone (TZ) of the sensor and hybridizes with the oligo(dT) strands of the nanoparticles. A characteristic red line is generated due to the accumulation of nanoparticles. The excess nanoparticles are captured by immobilized oligo(dA) at the control zone of the strip, giving a second red line. We have applied successfully the proposed OLR-dipstick assay to the genotyping of four SNPs in the drug-metabolizing enzyme genes CYP2D6 ((*)3 and (*)4) and CYP2C19 ((*)2 and (*)3). The results were in agreement with direct sequencing. 相似文献
524.
Aldostefano Porcari Yousuf Razvi Ambra Masi Rishi Patel Adam Ioannou Muhammad U. Rauf David F. Hutt Dorota Rowczenio Janet Gilbertson Ana Martinez-Naharro Lucia Venneri Carol Whelan Helen Lachmann Ashutosh Wechalekar Candida Cristina Quarta Marco Merlo Gianfranco Sinagra Philip N. Hawkins Marianna Fontana Julian D. Gillmore 《European journal of heart failure》2023,25(4):515-524
Aims
Transthyretin amyloid cardiomyopathy (ATTR-CM) is often assumed to be associated with wild-type TTR genotype (ATTRwt) in elderly patients (aged ≥70), some of whom are not offered genetic testing. We sought to estimate the prevalence, clinical characteristics and prognostic implications of transthyretin (TTR) variants among elderly patients diagnosed with ATTR-CM.Methods and results
Data from consecutive patients over 70 years of age diagnosed with ATTR-CM at the UK National Amyloidosis Centre between January 2010 and August 2022 were retrospectively evaluated. All patients underwent clinical evaluation, biochemical tests, echocardiography and TTR genotyping. The study outcome was all-cause mortality. The study population consisted of 2029 patients with ATTR-CM (median age 79 years at diagnosis, 13.5% females, 80.4% Caucasian). Variant ATTR-CM (ATTRv-CM) was diagnosed in 20.7% (n = 421) of the study population of whom 327 (77.7%) carried V122I, 47 (11.2%) T60A, 16 (3.8%) V30M and 31 (7.3%) other pathogenic TTR variants. During a median (range) follow-up of 29 (12–48) months, ATTRv-CM was associated with increased all-cause mortality compared to ATTRwt-CM, with the poorest survival observed in V122I-associated ATTRv-CM (p < 0.001). Univariable and multivariable logistic regression analyses in those with ATTR-CM showed younger age at diagnosis (odds ratio [OR] 0.85 per year, p < 0.001), female sex (OR 2.73, p < 0.001), Afro-Caribbean ethnicity (OR 65.5, p < 0.001), atrial fibrillation (OR 0.65, p = 0.015), ischaemic heart disease (OR 0.54, p = 0.007), peripheral polyneuropathy (OR 5.70, p < 0.001) and orthostatic hypotension (OR 6.29, p < 0.001) to be independently associated with ATTRv-CM.Conclusion
Up to 20.7% of elderly patients with ATTR-CM have a pathogenic TTR variant. These findings support routine sequencing of the TTR gene in all patients with ATTR-CM regardless of age. 相似文献525.
C. Fiorella Murillo Perez Stephanie Ioannou Iman Hassanally Palak J. Trivedi Christophe Corpechot Adriaan J. van der Meer Willem J. Lammers Pier Maria Battezzati Keith D. Lindor Frederik Nevens Kris V. Kowdley Tony Bruns Nora Cazzagon Annarosa Floreani Andrew L. Mason Aliya Gulamhusein Cyriel Y. Ponsioen Marco Carbone Ana Lleo Marlyn J. Mayo George N. Dalekos Nikolaos K. Gatselis Douglas Thorburn Xavier Verhelst Albert Parés Maria-Carlota Londoño Harry L. A. Janssen Pietro Invernizzi Raj Vuppalanchi Gideon M. Hirschfield Bettina E. Hansen Cynthia Levy the Global PBC Study Group 《Liver international》2023,43(7):1497-1506
Background and Aims
Patients with primary biliary cholangitis (PBC) and insufficient response to ursodeoxycholic acid (UDCA), currently assessed after 1 year, are candidates for second-line therapy. The aims of this study are to assess biochemical response pattern and determine the utility of alkaline phosphatase (ALP) at six months as a predictor of insufficient response.Methods
UDCA-treated patients in the GLOBAL PBC database with available liver biochemistries at one year were included. POISE criteria were used to assess response to treatment, defined as ALP <1.67 × upper limit of normal (ULN) and normal total bilirubin at one year. Various thresholds of ALP at six months were evaluated to predict insufficient response based on negative predictive value (NPV) and that with nearest to 90% NPV was selected.Results
For the study, 1362 patients were included, 1232 (90.5%) female, mean age of 54 years. The POISE criteria were met by 56.4% (n = 768) of patients at one year. The median ALP (IQR) of those who met POISE criteria compared to those who did not was 1.05 × ULN (0.82–1.33) vs. 2.37 × ULN (1.72–3.69) at six months (p < .001). Of 235 patients with serum ALP >1.9 × ULN at six months, 89% did not achieve POISE criteria (NPV) after one year of UDCA. Of those with insufficient response by POISE criteria at one year, 210 (67%) had an ALP >1.9 × ULN at six months and thus would have been identified early.Conclusions
We can identify patients for second-line therapy at six months using an ALP threshold of 1.9 × ULN, given that approximately 90% of these patients are non-responders according to POISE criteria. 相似文献526.
E. H. S. Choy D. A. Isenberg T. Garrood S. Farrow Y. Ioannou H. Bird N. Cheung B. Williams B. Hazleman R. Price K. Yoshizaki N. Nishimoto T. Kishimoto G. S. Panayi 《Arthritis \u0026amp; Rheumatology》2002,46(12):3143-3150